EuroBiotech: More Articles of Note

Newspapers

> ADC Therapeutics presented its first clinical data. The interim readouts came from phase 1 trials of ADCT-301 and ADCT-402 in different types of lymphoma. ADCT has embarked on a broad early-phase program using the $105 million it raised last year. Statement | More
 
> Shares in Quantum Genomics went on a multiday slide after it posted phase 2a data. The fall wiped more than 30% off the company’s share price. Traders drove down the stock after disagreeing with Quantum Genomics’ claim its hypertension data were positive. Release (PDF)

> Galapagos delayed the anticipated start of its triple combo cystic fibrosis study. The trial of the AbbVie-partnered combo is now due to start in the fourth quarter. Galapagos was aiming to get the trial underway by the middle of this year. The delay means Galapagos has ceded more ground to Vertex. Release (PDF)

> A phase 2 trial of Zealand Pharma’s glepaglutide met its primary endpoint. The trial linked the long-acting GLP-2 analogue to declines in fecal wet weight in patients with short bowel syndrome. Zealand plans to move the candidate into phase 3 next year. Statement
 
> Heidelberg Pharma landed a deal with Takeda. The agreement covers the development of antibody-targeted amanitin conjugates. Takeda has an option to license each candidate that emerges from the relationship. If that happens, Takeda will pay an upfront fee and up to $113 million per drug in milestones. Release
 
> Innovative Medical pulled out of a planned $30 million investment in Pluristem. Israel’s Pluristem attributed the U-turn to barriers created by Chinese regulations on the flow of capital out of the country. Globes

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.